CliffBio
small molecule

RELYVRIO

SODIUM PHENYLBUTYRATE; TAURURSODIOL

Loss of exclusivityJuly 2040latest FDA-listed patent expiry
CompanyAmylyx Pharmaceutical

Drug detail

Brand nameRELYVRIO
Active ingredientSODIUM PHENYLBUTYRATE; TAURURSODIOL
Strength3GM/PACKET; 1GM/PACKET
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2022
Marketing statusDISCN

Listed patents

PatentExpiresType
11583542July 2040product
10857162December 2033use U-3460
10251896December 2033use U-3460
9872865December 2033use U-3460
11071742December 2033product

Regulatory exclusivity

CodeExpires
ODE-411September 2029
NCESeptember 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.